Cronos Group Inc CRON shares are trading higher by 21% to $2.06 over the trailing five sessions, driven by the strong performance of the cannabis sector. Cannabis stocks have risen over the past week on news that the Department of Health and Human Services (HHS) proposed reclassifying marijuana to a lower-risk drug category.
See Also: Weed Stocks Skyrocket, Could There Be More Upside? Analyst Draws Scenarios
According to a letter dated August 29 seen by Bloomberg News, a high-ranking official from the Department of Health and Human Services has written to DEA Administrator Anne Milgram, urging the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
This shift reflects a significant change, as Schedule I substances include highly abused drugs like heroin.
The recommendation is informed by an FDA evaluation of marijuana's classification. The Controlled Substances Act categorizes substances based on medical usage, abuse potential and safety.
These shifting conditions facing the cannabis industry will be discussed at the Benzinga Cannabis Capital Conference so you won't want to miss out. Join us in Chicago this September 27-28.
Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
According to data from Benzinga Pro, Cronos Group has a 52-week high of $3.62 and a 52-week low of $1.64.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.